JPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments "The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 7cMay 7, 2024 7:18 AM Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 7:05 AM Form 10-Q Apellis Pharmaceuticals, For: Mar 31May 7, 2024 7:03 AM Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceMay 6, 2024 7:00 AM